# A Pharmacogenomic Study of Candesartan in Heart Failure

> **NCT00400582** · PHASE4 · COMPLETED · sponsor: **Montreal Heart Institute** · enrollment: 300 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Candesartan up to 32 mg daily

## Key facts

- **NCT ID:** NCT00400582
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400582, "A Pharmacogenomic Study of Candesartan in Heart Failure". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00400582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*